Showing results (591-600 of 688) with videos related to

Sort By:
Pageof 69
Arthritis Research & Therapy|January 19, 2015
A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosisYanjie Hao, Vivek Thakkar, Wendy Stevens, et al.
Annals of the Rheumatic Diseases|February 2, 2017
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trialsStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Annals of the Rheumatic Diseases|July 9, 2026
A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trialPaul Emery, Michael E Weinblatt, Vivian P Bykerk, et al.
Annals of the Rheumatic Diseases|July 15, 2020
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52Josef S Smolen, Philip Mease, Hasan Tahir, et al.
Rheumatology (Oxford, England)|December 15, 2010
Registries in systemic sclerosis: a worldwide experienceFelice Galluccio, Ulrich A Walker, Svetlana Nihtyanova, et al.
Clinical and Experimental Rheumatology|August 6, 2015
Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung diseaseOwen A Moore, Susanna M Proudman, Nicole Goh, et al.
Rheumatology and Therapy|October 9, 2022
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 StudyBernard G Combe, Yoshiya Tanaka, Maya H Buch, et al.
RMD Open|February 8, 2023
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitisGerd R Burmester, Stanley B Cohen, Kevin L Winthrop, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Jonathan Kay, et al.
Clinical and Vaccine Immunology : CVI|December 26, 2014
An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trialNina Wressnigg, Maikel V W van der Velden, Daniel Portsmouth, et al.
Pageof 69